Home ▸ News

Safety Review Committee for CARIN Trial recommends Phase 2a study to continue as planned

May 19, 2015

Ischemix, Inc. announced today that it has received a favorable safety report from the Safety Review Committee for the ongoing CARIN (contrast-induced acute kidney injury ("CI-AKI") in acute coronary syndrome patients undergoing coronary angiography) trial. On behalf of the committee, Ahmad Kahlil MD, Medical Monitor for the trial, made his formal report to Ischemix, the Sponsor of the trial, that the study is recommended to continue as planned. There were no signals of concern noted.

The CARIN trial is a randomized, double-blinded, placebo-controlled trial of Ischemix' lead compound, CMX-2043, for the prevention of contrast-induced acute kidney injury (CI-AKI) and cardiac injury in cardiac catheterization patients. Ischemix' previous Phase 2a trial successfully demonstrated the latter endpoint; the CARIN trial is also designed to confirm these results. To date the CARIN trial has enrolled 212 patients at 28 sites in the US and Canada.

Ischemix CEO David A. DeWahl, Jr. commented "The report by the Safety Review Committee is consistent with the results of our two previous clinical trials, in which CMX-2043 was shown to be safe and well tolerated at therapeutic dose levels." CMX-2043 is a new chemical entity based on a naturally-occurring compound. Ischemix holds recently issued composition-of-matter patents covering its portfolio of compounds.

The Safety Review Committee completed the planned review of the safety data on the first 150 subjects completing the 72-hour follow-up in the trial. Due to the timing of enrollment, the data for 156 subjects were reviewed. Data reviewed was limited to the reported adverse events and data submitted from the local laboratories.

Latest News

August, 2023

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

July 7, 2021

Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

March 25, 2019

Novel Compound for Treatment of Traumatic Brain Injury (TBI) Demonstrates Positive Results in a Preclinical Study

April 4, 2016

Ischemix Announces Results of Its Phase 2 CARIN Trial

January 5, 2016

Ischemix, Inc. to Present at Biotech Showcase™ on January 13, 2016

December 9, 2015

Ischemix, Inc. Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

September 30, 2015

Ischemix, Inc. Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients

August 12, 2015

Ischemix Elects Peter G. Milner, MD to Board of Directors

May 19, 2015

Safety Review Committee for CARIN Trial recommends Phase 2a study to continue as planned

March 24, 2015

Ischemix Appoints Clinical Trial Liaison

June 26, 2014

Ischemix Enrolls First Patient in Phase 2a Trial to Prevent Contrast-Induced Acute Kidney Inury

January 9, 2013

Ischemix Appoints new Chief Executive Officer

June 17, 2011

Ischemix Completes Phase 2a Clinical Trial

March 2, 2011

Ischemix Granted Composition of Matter Patent for CMX-2043

March 9, 2010

Ischemix Initiates Phase 2a Clinical Trial

August 13, 2007

Ischemix Completes Phase 1 Clinical Trial

April 5, 2007

Ischemix Initiates Clinical Development